Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Devyser Diagnostics, Audiocast, Q1'26

By Inderes4/27/2026, 9:00 AM
Devyser Diagnostics

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Jan Wahlström
00:02 - 03:17

Good morning and welcome to the Devyser Q1 2026 Earnings Call. My name is Jan Wahlström. I'm the CEO of Devyser and would like to thank you, everyone for joining our call today. On the call today, we have in addition to myself, also our CFO, Sabina Berlin. I will start with a short summary of highlights from the quarter before handing over to Sabina for a more detailed review of our financial results for January to March. And then we'll go through an update on our recent commercial activities. The first quarter posted a positive EBIT for the fourth consecutive quarter. As you know, we started the journey in the beginning of last year, focusing the company towards profitable growth. It's been a successful journey, and we're happy to deliver strong growth and positive EBIT. In the first quarter of the year, we continued to grow faster than the market. We grew 24.4% in local currency. We received quite a few orders from Thermo Fisher Scientific in this quarter, a step towards a more stable order pattern. We're also very pleased with the gross margin of 82%. It's better than full year 2025, and we will continue to work on improving cost of goods sold. EBIT came in at a positive 2.6 MSEK compared to last year's negative 14.8 MSEK in the first quarter. So we're growing faster than the market with a clear focus on profitable growth. In the first quarter, we signed the agreement to acquire CyberGene, a Swedish company with products in similar areas as Devyser, giving us a stronger commercial position in several markets. CyberGene is a Stockholm-based diagnostic company and has operated in the same market as Devyser for many years, providing Devyser with in-depth knowledge of CyberGene products and customers. The acquisition was completed on April 1st and we have already integrated the company in our daily operations. CyberGene has demonstrated steady growth, driven by a strong product offering and consistent market expansion, and will contribute positively to Devyser's gross profit and gross margin. As presented earlier in the year, in Q1, we also signed a significant agreement with Illumina, giving us the opportunity to do reagent rental on the European market. As we spoke about in the last quarter, we continue the ongoing MolDx application for a post-transplant kidney test as a service in the US. Since last quarter, we have gathered more clinical data and we are now analyzing the clinical samples. After that, we will send in a renewed application and hopefully we can have an approved product before the end of the year. At the same time, we continue to work on our FDA project in transplantation, and we've had very positive development here. We have all the six sites up and running, and we gather patients at a good pace and will continue to do so. We need 2026 and 2027 to be able to file in 2028 if everything develops in a positive way. With that, I would like to hand over to Sabina to share more details on our financial results for Q1 2026.

Sabina Berlin
03:18 - 06:11

Thank you Jan. I will continue with the summary of the financials for Q1. Revenue for January to March came in at 62 million, compared to 55 million in the same quarter of last year. That amounts to a quarter-over-quarter growth of 13%, which equals almost 25% in local currency. As we're still seeing FX headwinds with a strong SEK. Our revenue growth curve continues upwards in the rolling 12 months. Q2 and Q4 have historically been stronger based on distributed purchasing patterns, but we expect that to flatten out over time. We have a stable underlying growth that is very clear when we work with our growth numbers in local currency. North America keeps growing at a quick pace and made up 20% of sales in the quarter, built up from revenue from Thermo Fisher Scientific and a very strong performance from direct sales of the hereditary portfolio in the quarter. EMEA had a slower reported growth in the quarter, but all our direct markets are performing well and there will always be fluctuations between individual quarters. Asia Pacific remains at a small but steady level. Q1 saw the same growth in both direct sales and distributor sales of 12 and 13%, respectively, during the quarter. Apart from the distributors in the Middle East, our sales channels have seen limited impact from the current ongoing conflicts, and we have been able to ship according to plan on all orders. Gross margin came in at 81.6%, a healthy margin that shows the low production cost for our products. Q1 of 2025 at an even higher margin as part of the lumpiness in the margin that we saw last year. And that should now be reduced for 2026 and forward. Our EBIT for the quarter was 2.6 million, and we now have a full 12-month rolling of positive numbers. Last year's Q1 was heavily impacted by the reorganisation that we initiated early in 2025, and that we have been able to harvest the benefits from during the following quarters. We will continue to drive business with profitable growth and leverage both our strong product portfolio and innovation engine to drive growth and keep being careful with our cost base. We closed the quarter with 75 million in cash, not much below Q4 numbers. Cash flow from operating activities was 12 million positive for the quarter, just as strong as last quarter, showing that our cash flow now fully finances daily operations. Cash flow continues to be an important focus for us as we grow and invest; I remain confident that we will reach cash flow positive. This also includes investments within the foreseeable future. And with that, I hand back over to Jan.

Jan Wahlström
06:12 - 09:29

Thank you, Sabina. I'm pleased to share several promising highlights from our strong Q1. After a strong Q4, we continued with an equally strong Q1. 24% growth. We had good results across the board both in Europe and the US. Our direct business in the US grew multiple times, showing a continued strong position for us with our hereditary products. We have some challenges, as Sabina talked about in the Middle East, but managed to get some of those sales through at the end of the quarter. I'm just back from a productive and positive meeting with Thermo Fisher, and was happy to see that they continued to win new accounts and grow our joint business in a good way. Looking at the Illumina agreement, as you know, January 28th, we announced that we are now a Systems Integrator with Illumina and entered into a collaborative framework agreement. Illumina is by far the market leader when it comes to the DNA sequencing market. We presented the product in the previous quarterly report, but can now add that we see a strong interest in this solution from our customers. The reagent rental model is a proven business model in our market, and we believe it will give us many opportunities to win over more business in the quarters to come. Moving on to an update on our partnership with Thermo Fisher for our transplantation products. Q1 was a good quarter where we have, as I mentioned before, seen several new accounts. Our e-commerce sales have developed well, but it's good to see that our cfDNA products also see good market uptake. Now in Europe, we're making significant progress related to having cfDNA become recognized and endorsed as a preferred rule out test on biopsies and supported by the new reimbursement schemes. North America had another strong quarter, both in kit sales to end customers as well as good development in our lab. The kit sales growth came mainly from our cystic fibrosis and Thalassemia products. The collaboration with Cyted continues in a good way. At the same time as we're working on more customers for the lab. Sales have developed well in the quarter in Europe as well. But the big news this quarter was the Illumina agreement. On the product side, we launched IVDR products for cystic fibrosis late last year and Thalassemia in Q1. These launches have been successful with great interest from customers. That has given high growth numbers on tests sold in this quarter. Going forward, we now have four quarters in a row with positive EBIT and continue on profitable growth. We also keep our focus on becoming a one-stop solution for clinical genomic labs. With new launches and moving more of our products to IVDR status. We will continue focusing on our collaborations with Thermo and Illumina, collaborations that give us access to bigger markets and strong partner organizations. Our focus remains on continuous improvement and increased profitability alongside strong top line growth. With that, I would like to open up for questions.

Operator
09:31 - 09:49

If you wish to ask a question, please dial Pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Ulrich Trattner from DNB Carnegie. Please go ahead.

Ulrich Trattner
09:51 - 10:18

Thank you very much, Jan and Sabina. And a few questions on my end. You talked about some smaller orders coming in from Thermo Fisher in Q1 to soften the curve. Is it possible in any way to quantify this, and should we estimate slightly fewer orders coming in in Q2, when they historically have put in larger orders?

Jan Wahlström
10:21 - 10:39

I cannot give an exact comment because I don't know the orders coming in in the quarters to come. But we see it as a positive sign that we start to get orders in Q1 and see that it's going to be less lumpy going forward.

Ulrich Trattner
10:42 - 11:03

Hi, Anna. I understand that you don't have the full scope of Q2, but my question is whether this is just a smoothing of the curve or if this should be seen as a trend in accelerated customer onboarding from Thermo Fisher on your transplantation product.

Jan Wahlström
11:06 - 11:22

I cannot comment on that in detail. But as I said, we had a positive meeting and we see an onboarding of new customers on the Thermo Fisher side when it comes to our transplantation products, if that is going to show in the numbers going forward, it's still to be seen.

Ulrich Trattner
11:25 - 11:38

Fair enough. And just if you can highlight how important is this trigger of yours to obtain MolDx reimbursement, as you've stated that hopefully will be done before year end?

Jan Wahlström
11:40 - 11:43

I didn't hear the beginning of the question. Can you repeat the beginning of the question?

Ulrich Trattner
11:44 - 11:53

I just thought of how important it is for volume uptake. Beyond the growth we're currently seeing that you obtain MolDx before year end.

Jan Wahlström
11:53 - 12:26

I mean, of course it's important for us to get the MolDx approval. We worked on it for a long time, and we believe it's an important way to reach customers in the US. As you know, service as a business is a big part of the transplant business. So it's something that will be important. And when we have that approval, and we believe that we are going to have it, as you said, at the end of the year. But then, it's difficult to quantify. It's a new business model. And I think we have to wait and see.

Ulrich Trattner
12:29 - 12:50

On the other hand, a commercial collaboration with Quest. How is that evolving? And you have obtained cost coverage for RHD, or been included in the cost coverage for your RHD screening test in the US? Are there any changes in testing volume, anything that you can give us some more granularity on?

Jan Wahlström
12:52 - 13:19

The collaboration with Quest is developing well. As we see, it's in a good way. I cannot give you any numbers on the sales to them, but it's been very positive to get the RHD coverage. That's mainly for our own lab, but it's developing in a good way with Quest. And we're very positive that they have this product, and hopefully we can work to get more products into their portfolio.

Ulrich Trattner
13:21 - 13:57

Okay, great. And just a question on the Illumina collaboration, which will, I guess, have a financial impact first round from Q2 onwards. So first of all, you talk about some initial high interest. It sounds like if you can elaborate on that, please, as well as is there any risk we should see, given that this is a reagent rental business, that we should expect some hampering of margins in the near term or just financially? How should we view this in the short run?

Jan Wahlström
13:58 - 14:39

I think in the short run, we should see it as a possibility for us to get good growth. And it will, of course, be a little bit less margin on some of those deals in the short run for that, but it will increase the top line sales and the total profitability will definitely be better on each customer. Regarding the interest that you asked about, as I said, we have a number of different accounts that are showing interest, and we've seen that across different parts of Europe. And as soon as we have agreements in place, we will, of course, inform you about that as well.

Ulrich Trattner
14:42 - 15:10

And is there any way you can quantify how much more contracts of this kind would generate over, say, a five-year period on a reagent rental business, given that you are increasing the average sales price per test? I would assume so over a five year period, given that you would have a little bit less margin, how would the profitability look? Ballpark. Is it 20, 30, 40% more over a five-year period? Or what does it look like?

Jan Wahlström
15:12 - 15:34

They are all individual contracts and negotiated. But it's definitely higher in the revenue per contract. And we'll see if we can give some more detailed information about that going forward. But I don't have that as we're still in discussion with the first customers. And when we have the first agreements in place, then it's probably easier to answer that question.

Ulrich Trattner
15:36 - 16:08

Great. And just last question on my end, I guess this would be addressed to you, Sabina. You reported 12 million in operational cash flow. It looks like really strong cash flow here in Q1, 120% cash conversion to EBITDA. And you sound fairly optimistic regarding reaching free cash flow positive here in short, is there any one-offs that we should not extrapolate here in Q1, and what is a reasonable cash conversion ratio going forward?

Sabina Berlin
16:11 - 17:00

No, we don't foresee any one-offs that will impact the upcoming quarters. There will be continuous and well-balanced investments, both in our commercialization in the US and in our R&D. But we do think that our free cash flow will also move towards the positive. And there are no cash flow one-offs in Q1 either impacting this. We did see strong sales in Q4 and that has had a positive effect on our accounts receivables, but not in terms of one-offs.

Ulrich Trattner
17:02 - 17:07

Okay, great. And just what is a feasible long-term cash conversion ratio?

Sabina Berlin
17:08 - 17:10

I don't think we'll be sharing that at this time.

Ulrich Trattner
17:12 - 17:16

Okay. Well, thank you very much, both of you. And I'll get back into the queue.

Sabina Berlin
17:17 - 17:18

Thank you.

Operator
17:21 - 17:26

The next question comes from Filip Wiberg from Pareto Securities. Please go ahead.

Filip Wiberg
17:28 - 18:03

Hi. Hi. I've got two questions, but I'll take them one by one. So first, maybe a little bit of a follow-up on the Thermo Fisher sales here. So I'm just thinking about the rest of the year now, the growth outlook and what kind of visibility that you have. And so you wrote in the report that you see clear continuity in the growth trend established during 25. And obviously, we've had quite a good growth rate in Q1. But how should we think of that now going forward? Do you think the growth rate in this quarter was the highest that it's going to be, or do you see an acceleration or what's the expectations there?

Jan Wahlström
18:04 - 18:25

Thank you, Filip. As I answered the previous question, I cannot comment on revenue for Q2 to Q4 from Thermo. And one reason for that is because we don't have those orders and we don't have that visibility. It's something that we will see when we get there.

Filip Wiberg
18:28 - 18:48

All right. Okay. Then one other thing that could drive growth is obviously new product launches. I don't know if you've talked about that a lot lately, but have you done any new product launches this year? Or are you planning for any sort of launches that you expect to drive growth in any meaningful way going forward?

Jan Wahlström
18:49 - 19:17

Well, we did have the launch of the CFTR product for IVDR in Q4 and the Thalassemia one in this quarter, and we've seen very good uptake in the number of tests for those two products in this time. And as you know, CFTR is one of our biggest products. So a good uptake in that one is significant for us and very important. Apart from that, we don't have any other launches in Q1. But of course, we're working hard to see if we can get some products out in the second quarter and onwards as well.

Filip Wiberg
19:20 - 19:23

Okay. Okay. Thank you. Yes, that was all for me.

Operator
19:28 - 19:40

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. The next question comes from Ludvig Lundgren from Nordea. Please go ahead.

Ludvig Lundgren
19:42 - 20:05

Yes. Hi. And thank you for taking my question. So I also have two, and starting off on EMEA, where organic growth slowed a bit sequentially in Q1. But that follows, of course, the very strong Q4. So can you comment a bit about this phasing and what to expect in terms of phasing for 2026.

Jan Wahlström
20:08 - 20:35

Yes. When it comes to EMEA, you're right in that comment, and as Sabina said during the call, the quarters can go a little bit up and down. And we've seen a good development in Europe. And as I also said in the call, when it comes to the phasing, I don't have any exact data to comment on the phasing going forward. But we have a strong belief that we will continue on a good growth pattern both in Europe and the US.

Ludvig Lundgren
20:39 - 20:56

Okay. Thanks. Very clear. And then a second one on the CyberGene acquisition, which I guess will start contributing to growth here in Q2. So I just wonder if you can elaborate how this is expected to affect operating expenses and margins and also cash flow.

Jan Wahlström
20:59 - 21:30

We can. Yes, absolutely. When it comes to the margins, the margin that the CyberGene products have. We said that previously as well, that they are actually higher than what we have. So that should impact on the positive side. When it comes to the total volume of sales of the CyberGene products, it is very low. I don't think that it will be visible in the bigger scheme on the numbers. But it is a positive contributor.

Ludvig Lundgren
21:34 - 21:37

Okay. Thanks. Very clear. I'll jump back into the queue.

Operator
21:40 - 21:44

The next question comes from Ulrich Trattner from DNB Carnegie. Please go ahead.

Ulrich Trattner
21:47 - 22:15

Thank you, and thanks for taking my follow-up questions. Accounting-wise, capitalized R&D or net capitalized R&D. We have seen quite stable levels for the last few quarters. And where should we expect sort of capitalized R&D going? Especially as you're approaching a few new product launches. I would assume that that would come down. What to expect here.

Jan Wahlström
22:17 - 22:47

Ulrik, it's a good question. What we said before, and I believe it's a good statement still, is that we don't see it coming up, and we see it to be fairly stable, at least during the time when we are doing the FDA studies, because a lot of the capitalized development comes from the MolDx and the FDA work we do. But, I would say flattish is probably the best estimate going forward.

Ulrich Trattner
22:49 - 23:09

Great. Thank you. And for my last question, also accounting-wise, going back to the fact that you didn't want to state any specific targets for cash conversion, if I were to rephrase it and ask what would be a fair net working capital to sales ratio for Devyser in the near to medium term?

Sabina Berlin
23:14 - 23:52

Well, thank you. It's a number. We also don't publicly announce this, but our expectation is that both operating cash flow will continue to strengthen and free cash flow will go above zero. And as we grow our margins, that will continue in a positive direction, but it will also give us an opportunity to invest in continued R&D to support our growth.

Ulrich Trattner
23:55 - 24:13

Sure. And I guess I can rephrase it further then. Yeah. Are you anticipating to do any larger investments into working capital here in the near term, or will the cash flow be more dependent on what you achieve in sales?

Sabina Berlin
24:14 - 24:37

I think working capital ratio will pretty much stay the same. We will grow our inventory in proportion to our sales, and when it comes to accounts receivable and accounts payable, they will also go very much in proportion to our cost and revenue side. So I think when you do your calculations, you can assume pretty much the same ratios.

Ulrich Trattner
24:39 - 24:42

Perfect. That's great. Thank you very much again.

Jan Wahlström
24:45 - 24:45

Thank you Rick.

Sabina Berlin
24:46 - 24:46

Thank you.

Operator
24:49 - 24:55

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Jan Wahlström
24:59 - 25:04

Again, thank you, everyone for joining our call today and looking forward to the next quarterly call.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…